In most laboratories, creatinine still travels with a single red flag: a fixed “panic value” that triggers the phone call to the clinician. It looks reassuringly simple. Yet the evidence around creatinine tells a more uncomfortable story: the number that should keep us awake at night is not universal, and sometimes the truly dangerous change hides well inside the “normal” range.
Outcome-based studies in children are a good starting point. Using tens of thousands of pediatric biochemistry results and high-dependency or ICU admission as the outcome, Du and colleagues derived a critical serum creatinine threshold of about 129 µmol/L (≈1.46 mg/dL) for several routine tests, including creatinine (Du et al., 2018). Above this point, the conditional probability of serious deterioration reached 90 percent. From a panic-value perspective, this is radically different from the traditional approach that extrapolates pediatric limits from adult reference intervals. It shows that a child can look only modestly abnormal on the report sheet yet sit on the edge of clinical collapse.
For adults, the situation is even more layered. In an inulin-clearance study, Couchoud et al. mapped serum creatinine to measured GFR and proposed sex-specific cut-offs for different levels of renal impairment. In men, values around 177 µmol/L (≈2.0 mg/dL) already corresponded to a GFR below 30 mL/min/1.73 m², while women reached the same level of impairment at about 146 µmol/L (≈1.65 mg/dL) (Couchoud et al., 1999). If a laboratory uses a single panic threshold for both sexes, it will systematically underestimate risk in women. A panic number that ignores muscle mass and sex quietly bakes inequity into the reporting system.
Risk does not start at “renal failure” either. In a community cohort of 50-year-old men followed for 20 years, myocardial infarction and cardiovascular death increased significantly once creatinine-based eGFR dropped below roughly 98 and 92 mL/min respectively (Soveri et al., 2009). In type 2 diabetes, an eGFR at or below 84.8 mL/min/1.73 m² and a urinary albumin–creatinine ratio above 15.5 mg/g, both still within the normal range, predicted diabetic kidney disease and cardiovascular events as strongly as more complex multivariable models (Gao et al., 2022). From a patient-safety angle, this means that a rigid panic threshold at “very high creatinine” misses the long hazardous slope where preventable damage accumulates.
Acute illness adds yet another twist. In critical COVID-19, a creatinine cut-off as low as 0.83 mg/dL separated survivors from non-survivors, when combined with inflammatory markers such as IL-6 and liver tests (Pal et al., 2022). In advanced cirrhosis, the long-used 1.5 mg/dL cut-off for acute kidney injury is now questioned; small absolute rises from baseline, even within the reference interval, carry major prognostic weight (Fagundes et al., 2015). The uncomfortable implication is that what counts as a “panic” creatinine in ICU or in cirrhosis may be a value that would be ignored on an outpatient report.
Even specimen type and dilution complicate the picture. Large forensic and clinical series show that fixed urine creatinine cut-offs used to label samples as “dilute” or “adulterated” can unfairly classify women, who naturally have lower muscle mass and creatinine excretion (Arndt, 2009). Salivary creatinine, proposed as a low-cost screening tool, has its own ROC-derived thresholds that cannot be naively translated back to serum (Pham, 2017). The same analyte, different matrix, completely different critical numbers.
All of this suggests that the idea of a single, context-free creatinine panic value is intellectually comfortable but clinically fragile. A safer strategy is to think in tiers. One tier is a true emergency threshold, often around the point where GFR falls below 30 mL/min/1.73 m² in adults or above the outcome-based threshold in children, and which should always trigger rapid direct contact. A second tier consists of “high-risk alerts” inside the reference interval: modest rises from baseline, small decrements in eGFR in diabetics or high-risk cardiovascular patients, or increases in creatinine during critical illness that signal impending decompensation. A third tier is interpretive: automated comments that remind clinicians that a “normal” creatinine in a sarcopenic older adult may not be normal at all, and that cystatin C or measured GFR may be needed (Yim et al., 2022).
Creatinine is therefore not a single alarm bell but a whole panel of warning lights, each calibrated to age, sex, muscle mass and clinical context. Treating it as one magic panik değeri is convenient for the lab, but dangerously optimistic for the patient.
References
Arndt, T. (2009). Urine-creatinine concentration as a marker of urine dilution: Reflections using a cohort of 45,000 samples. Forensic Science International, 186(1–3), 48–51. https://doi.org/10.1016/j.forsciint.2009.01.010
Couchoud, C., Pozet, N., Labeeuw, M., & Pouteil-Noble, C. (1999). Screening early renal failure: Cut-off values for serum creatinine as an indicator of renal impairment. Kidney International, 55(5), 1878–1884. https://doi.org/10.1046/j.1523-1755.1999.00411.x
Du, H., Markus, C., Metz, M., Feng, M., & Loh, T. P. (2018). Derivation of outcome-based pediatric critical values. American Journal of Clinical Pathology, 149(4), 324–331. https://doi.org/10.1093/ajcp/aqx165
Fagundes, C., Barreto, R., Rodriguez, E., Graupera, I., Poch, E., Solà, E., Fernández, J., & Ginès, P. (2015). Reply to: A cut-off serum creatinine value of 1.5 mg/dL for AKI – To be or not to be. Journal of Hepatology, 62(3), 743–744. https://doi.org/10.1016/j.jhep.2014.11.039
Gao, Z., Zhu, Y., Sun, X., Zhu, H., Jiang, W., Sun, M., Wang, J., Liu, L., Zheng, H., Qin, Y., Zhang, S., Yang, Y., Xu, J., Yang, J., Shan, C., & Chang, B. (2022). Establishment and validation of the cut-off values of estimated glomerular filtration rate and urinary albumin-to-creatinine ratio for diabetic kidney disease: A multi-center, prospective cohort study. Frontiers in Endocrinology, 13, 1064665. https://doi.org/10.3389/fendo.2022.1064665
Pal, K., Molnar, A. A., Hutanu, A., Szederjesi, J., Branea, I., Timar, A., & Dobreanu, M. (2022). Inflammatory biomarkers associated with in-hospital mortality in critical COVID-19 patients. International Journal of Molecular Sciences, 23(18), 10423. https://doi.org/10.3390/ijms231810423
Pham, T. A. V. (2017). Validation of the salivary urea and creatinine tests as screening methods of chronic kidney disease in Vietnamese patients. Acta Odontologica Scandinavica, 75(8), 551–556. https://doi.org/10.1080/00016357.2017.1356467
Soveri, I., Ärnlöv, J., Berglund, L., Lind, L., Fellström, B., & Sundström, J. (2009). Kidney function and discrimination of cardiovascular risk in middle-aged men. Journal of Internal Medicine, 266(4), 406–413. https://doi.org/10.1111/j.1365-2796.2009.02122.x
Yim, J., Son, N.-H., Kim, K. M., Yoon, D., Cho, Y., Kyong, T., Moon, J.-Y., Yi, T. I., Lee, S.-G., Park, Y., Lee, J. J., Kim, K.-A., Lee, J. E., & Kim, J.-H. (2022). Establishment of muscle mass-based indications for the cystatin C test in renal function evaluation. Frontiers in Medicine, 9, 1021936. https://doi.org/10.3389/fmed.2022.1021936